Comparative Proteomic Analysis in Serum of Former Uranium Miners with and Without Radon Induced Squamous Lung Cancer

Overview

Journal J Occup Med Toxicol

Publisher Biomed Central

Specialty Environmental Health

Date 2019 Mar 30

PMID 30923558

Citations 2

Authors

Simone Helmig

Gunter Lochnit

Joachim Schneider

Affiliations

Soon will be listed here.

Abstract

Summary: Former uranium miners of the Wismut Company, East Germany, have been exposed to ionizing radiation from radon decay products and therefore were at high risk for lung cancer. Since histological types of cancer in the so called Wismut cohort revealed an association of high radon exposure with a higher relative frequency of squamous cell carcinoma (SqCC), we used comparative proteomic analysis to identify differentially expressed proteins in serum exposed uranium miners with SqCC.

Methode: Pooled sera of exposed former uranium miners without lung disease and pooled sera of former uranium miners with SqCC were analysed by 2-D gel electrophoresis. MALDI-TOF-MS was performed from reproducable, significantly, at least 5-fold up-regulated protein spots. Proteins were identified by MASCOT peptide mass fingerprint search. Additionally a receiver operating characteristic curve for CYFRA 21-1 was created.

Results: The protein spots were identified as Keratin 10 (K10), Keratin 1 (K1), complement factor H (CFH) and a haptoglobin (Hpt) fragment. The sensitivity for CYFRA 21-1 reveals 60% at a specifity of 95 and 80% at a specifity of 80%. Plotting the sensitivity against specifity reveals an AUC of 0.88.

Conclusion: In SqCC Keratin 10 and 1 were strongly induced. This was associated with CYFRA 21-1, confirming the cytokeratin fragment as a tumormarker.

Citing Articles

Quantitative Proteomics Analysis of Differentially Expressed Proteins in Serum of Former Uranium Miners by Isobaric Tags for the Relative and Absolute Quantitation.

Dang X, Lin H, Yuan Y, Yang B, Dong J, Zhang Z Dose Response. 2021; 19(4):15593258211056190.

PMID: 34819815 PMC: 8606944. DOI: 10.1177/15593258211056190.

Complement System: Promoter or Suppressor of Cancer Progression?.

Revel M, Daugan M, Sautes-Fridman C, Fridman W, Roumenina L Antibodies (Basel). 2020; 9(4).

PMID: 33113844 PMC: 7709131. DOI: 10.3390/antib9040057.

References

Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B . p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer. 1999; 80(12):1987-94. PMC: 2363153. DOI: 10.1038/sj.bjc.6690632. View

Jacob J, Coulombe P, Kwan R, Omary M . Types I and II Keratin Intermediate Filaments. Cold Spring Harb Perspect Biol. 2018; 10(4). PMC: 5880164. DOI: 10.1101/cshperspect.a018275. View

Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C . Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics. 2011; 10(12):M111.010298. PMC: 3237079. DOI: 10.1074/mcp.M111.010298. View

. Ionizing radiation, part 2: some internally deposited radionuclides. Views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 14-21 June 2000. IARC Monogr Eval Carcinog Risks Hum. 2001; 78(Pt 2):1-559. PMC: 5220265. View

Walsh L, Grosche B, Schnelzer M, Tschense A, Sogl M, Kreuzer M . A review of the results from the German Wismut uranium miners cohort. Radiat Prot Dosimetry. 2014; 164(1-2):147-53. DOI: 10.1093/rpd/ncu281. View

Cui T, Chen Y, Knosel T, Yang L, Zoller K, Galler K . Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol. 2011; 39(1):161-8. DOI: 10.3892/ijo.2011.1010. View

Okano T, Seike M, Kuribayashi H, Soeno C, Ishii T, Kida K . Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. Int J Oncol. 2016; 48(3):945-52. PMC: 4750543. DOI: 10.3892/ijo.2016.3330. View

SCHUTTMANN W . Schneeberg lung disease and uranium mining in the Saxon Ore Mountains (Erzgebirge). Am J Ind Med. 1993; 23(2):355-68. DOI: 10.1002/ajim.4700230212. View

Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M . Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998; 4(10):2511-20. View

10.

Koch P, Roop D . The role of keratins in epidermal development and homeostasis--going beyond the obvious. J Invest Dermatol. 2004; 123(5):x-xi. DOI: 10.1111/j.0022-202X.2004.23495.x. View

11.

Magin T, Vijayaraj P, Leube R . Structural and regulatory functions of keratins. Exp Cell Res. 2007; 313(10):2021-32. DOI: 10.1016/j.yexcr.2007.03.005. View

12.

Riihila P, Nissinen L, Ala-Aho R, Kallajoki M, Grenman R, Meri S . Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2013; 134(2):498-506. DOI: 10.1038/jid.2013.346. View

13.

Schneider J . Tumor markers in detection of lung cancer. Adv Clin Chem. 2006; 42:1-41. DOI: 10.1016/s0065-2423(06)42001-1. View

14.

Schneider J, Presek P, Braun A, Woitowitz H . Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut). Am J Ind Med. 1999; 36(6):602-9. DOI: 10.1002/(sici)1097-0274(199912)36:6<602::aid-ajim2>3.0.co;2-m. View

15.

Chang Y, Lai Y, Chu Y, Lee M, Huang C, Wu S . Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry. Am J Cancer Res. 2016; 6(8):1828-36. PMC: 5004083. View

16.

Paramio J, Casanova M, Segrelles C, Mittnacht S, Lane E, Jorcano J . Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol. 1999; 19(4):3086-94. PMC: 84102. DOI: 10.1128/MCB.19.4.3086. View

17.

Popp W, Plappert U, Muller W, Rehn B, Schneider J, Braun A . Biomarkers of genetic damage and inflammation in blood and bronchoalveolar lavage fluid among former German uranium miners: a pilot study. Radiat Environ Biophys. 2001; 39(4):275-82. DOI: 10.1007/s004110000072. View

18.

Kreuzer M, Fenske N, Schnelzer M, Walsh L . Lung cancer risk at low radon exposure rates in German uranium miners. Br J Cancer. 2015; 113(9):1367-9. PMC: 4815799. DOI: 10.1038/bjc.2015.324. View

19.

Korfei M, Schmitt S, Ruppert C, Henneke I, Markart P, Loeh B . Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J Proteome Res. 2011; 10(5):2185-205. DOI: 10.1021/pr1009355. View

20.

Ajona D, Castano Z, Garayoa M, Zudaire E, Pajares M, Martinez A . Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 2004; 64(17):6310-8. DOI: 10.1158/0008-5472.CAN-03-2328. View